Boston Scientific Corporation

• Valuation8.5 / 10
• Management8.5 / 10
• Balance Sheet6 / 10
• Profitability6.5 / 10
• Revenue Growth6 / 10
• Risk Assessment7.5 / 10
• Competitive Moat8 / 10
• Earnings Quality8 / 10
• Capital Efficiency5.5 / 10

While consensus earnings expectations adjusted downward post-earnings—trimming FY2026 consensus EPS to $3.24 and FY2027 consensus EPS to $3.38,, —the operational inflection beginning in FY2027-FY2028 is backed by visible catalysts. Boston Scientific plans to launch FARAPULSE Ultra and enter the intracardiac echocardiography market at scale in H2 2027. Simultaneously, the pending acquisition of Penumbra strengthens peripheral thrombectomy capabilities, and the company's enterprise-wide $500M efficiency program is structured to realize over half of its savings exiting 2027.^1,4

Valuation creates an attractive margin of opportunity. At $44.51, Boston Scientific trades at 13.23x forward earnings, sitting below medical technology peers such as Stryker (17.86x) and Edwards Lifesciences (26.13x). The house fair value midpoint of $65.94 reflects disciplined intrinsic cash flow modeling with operating margins expanding from 26.5% in FY2026 to 28.5% by FY2030 on an 8.0211% cost of equity, confirming our Strong Buy recommendation.^2,3

In the bear case, persistent standalone volume contraction in WATCHMAN and aggressive pricing from competitor PFA launches constrain organic revenue growth below guided levels. Gross margin compression from product mix and delayed execution of the $500M efficiency program hold operating margins below 25.0%, with annual EPS growth restricted to 4.5% to 5.0%.

Standalone WATCHMAN volume contraction is running at mid-teens negative, compounded by a 20% cut to physician reimbursement fees and competitor PFA launches in H2 2026 and H1 2027,. This drives consolidated organic growth below 3.0%, breaking the 7.5% recovery profile modeled for FY2028.⁴

The base case models management's updated FY2026 organic revenue guidance of 5% to 6% and consensus EPS of $3.24. In FY2027, revenue advances 4.85% with EPS of $3.38 as product mix headwinds linger and Penumbra is integrated. Commencing in FY2028, revenue growth accelerates to 7.5% and operating margins reach 28.5% by FY2030 as FARAPULSE Ultra scales and $500M in efficiency savings are realized,.^1,4

Capital deployment prioritizes operational reinvestment, strategic tuck-in technology M&A, and programmatic share repurchases. Capital expenditures totaled $876M in FY2025, supporting catheter production scale and advanced manufacturing lines, with the net reinvestment rate held constant at 18.0% of operating profit across the five-year house forecast. The company demonstrated disciplined capital return by completing a $2,000M accelerated share repurchase in Q2 2026, retiring approximately 40 million shares. Strategic capital allocation included a $1,500M investment in MiRus for a 34% equity stake and TAVR acquisition option, alongside the pending acquisition of Penumbra in H2 2026. Debt management remains sound, with total debt of $12,418M as of FY2025 ($12,624M as of October 2026) supported by strong operating cash flows.

Forecast cash flows / share

US$11.81

Terminal value / share

US$50.49

Signed net debt / current share

US$7.21